Alliance for Pandemic Preparedness

April 16, 2021

Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients

Category:

Topic:

Keywords (Tags):

  • Observed safety and reactogenicity to 2 doses of mRNA vaccines (Moderna and Pfizer-BioNTech) weas similar to that reported in clinical trials among a cohort of US solid organ transplant recipients recruited through social media (n=741). Local site reactions were reported by 85% and 78% of participants and systemic reactions were reported by 49% and 69% of participants following the first and second doses, respectively. Younger participants were more likely to develop systemic reactions following either dose. No anaphylaxis, neurologic diagnoses, or SARS-CoV-2 diagnoses were reported.

Ou et al. (Apr 9, 2021). Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. https://pubmed.ncbi.nlm.nih.gov/33859151